Our top pick for
Beginners

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Rexahn Pharmaceuticals, Inc is a biotechnology business based in the US. Rexahn Pharmaceuticals shares (REXN) are listed on the NASDAQ and all prices are listed in US Dollars. Rexahn Pharmaceuticals employs 5 staff and has a trailing 12-month revenue of around USD$1.2 million.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Mobile users
52-week range | USD$1.72 - USD$14.8 |
---|---|
50-day moving average | USD$7.198 |
200-day moving average | USD$9.5088 |
Wall St. target price | USD$3 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | USD$-4.834 |
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Revenue TTM | USD$1.2 million |
---|---|
Gross profit TTM | USD$0 |
Return on assets TTM | -33.73% |
Return on equity TTM | 0% |
Profit margin | 0% |
Book value | $2.925 |
Market capitalisation | USD$2 million |
TTM: trailing 12 months
There are currently 13,595 Rexahn Pharmaceuticals shares held short by investors – that's known as Rexahn Pharmaceuticals's "short interest". This figure is 358.8% up from 2,963 last month.
There are a few different ways that this level of interest in shorting Rexahn Pharmaceuticals shares can be evaluated.
Rexahn Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Rexahn Pharmaceuticals shares currently shorted divided by the average quantity of Rexahn Pharmaceuticals shares traded daily (recently around 271900). Rexahn Pharmaceuticals's SIR currently stands at 0.05. In other words for every 100,000 Rexahn Pharmaceuticals shares traded daily on the market, roughly 50 shares are currently held short.
However Rexahn Pharmaceuticals's short interest can also be evaluated against the total number of Rexahn Pharmaceuticals shares, or, against the total number of tradable Rexahn Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Rexahn Pharmaceuticals's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Rexahn Pharmaceuticals shares in existence, roughly 0 shares are currently held short) or 0.0008% of the tradable shares (for every 100,000 tradable Rexahn Pharmaceuticals shares, roughly 1 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Rexahn Pharmaceuticals.
Find out more about how you can short Rexahn Pharmaceuticals stock.
We're not expecting Rexahn Pharmaceuticals to pay a dividend over the next 12 months.
Rexahn Pharmaceuticals's shares were split on a 1:12 basis on 12 April 2019. So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Rexahn Pharmaceuticals shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Rexahn Pharmaceuticals shares which in turn could have impacted Rexahn Pharmaceuticals's share price.
Over the last 12 months, Rexahn Pharmaceuticals's shares have ranged in value from as little as $1.72 up to $14.8. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Rexahn Pharmaceuticals's is 0.973. This would suggest that Rexahn Pharmaceuticals's shares are less volatile than average (for this exchange).
As of November 5, 2020, Rexahn Pharmaceuticals, Inc. was acquired by Ocuphire Pharma, Inc., in a reverse merger transaction. Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of cancer. The company's product pipeline include RX-3117, which is in Phase IIa clinical trials for the treatment of patients with relapsed or refractory metastatic pancreatic cancer, as well as bladder, colon, lung and cervical cancer. It is also developing RX-0301, which is in preclinical development stage for the treatment of hepatocellular carcinoma. Rexahn Pharmaceuticals, Inc. has collaboration agreements with Zhejiang Haichang Biotechnology Co., Ltd.; and BioSense Global LLC. The company is headquartered in Rockville, Maryland.
Everything we know about the CDT Environmental Technology Investment Holdings Limited IPO, plus information on how to buy in.
Everything we know about the Viant Technology Inc IPO, plus information on how to buy in.
Steps to owning and managing EVGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ETL, with 24-hour and historical pricing before you buy.
Steps to owning and managing EQBK, with 24-hour and historical pricing before you buy.
Steps to owning and managing EIGI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ELTK, with 24-hour and historical pricing before you buy.
Steps to owning and managing DNKN, with 24-hour and historical pricing before you buy.
Steps to owning and managing DKL, with 24-hour and historical pricing before you buy.
Steps to owning and managing DMAC, with 24-hour and historical pricing before you buy.